Summary by Futu AI
Clover Biopharmaceuticals Limited (“Clover Bio-B”) filed with Hong Kong Trading and Settlement Limited on 3 April 2024 with Hong Kong Trading and Settlement Limited, reporting the stock changes as of 31 March 2024. The report showed that the company's regulated/registered share capital remained unchanged, totaling $200,000, with a face value of $0.0001 per share, and the total number of shares was 2,000,000,000 shares. In terms of stock options, 52,500 share options were exercised during the month and 26,000 share options expired under the Initial Public Offering Plan approved on April 15, 2021. In addition, 1,315,986 share options expired this month under the Initial Public Offering Possession Option Plan approved on September 26, 2021. The total amount of capital gained from the exercise of options during the month was HK$420. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.